JP2024517789A5 - - Google Patents

Info

Publication number
JP2024517789A5
JP2024517789A5 JP2023567067A JP2023567067A JP2024517789A5 JP 2024517789 A5 JP2024517789 A5 JP 2024517789A5 JP 2023567067 A JP2023567067 A JP 2023567067A JP 2023567067 A JP2023567067 A JP 2023567067A JP 2024517789 A5 JP2024517789 A5 JP 2024517789A5
Authority
JP
Japan
Prior art keywords
substituted
pharmaceutically acceptable
acceptable salt
unsubstituted
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023567067A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024517789A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/026676 external-priority patent/WO2022232360A1/en
Publication of JP2024517789A publication Critical patent/JP2024517789A/ja
Publication of JP2024517789A5 publication Critical patent/JP2024517789A5/ja
Pending legal-status Critical Current

Links

JP2023567067A 2021-04-30 2022-04-28 グルコセレブロシダーゼ活性の小分子モジュレータ及びその使用 Pending JP2024517789A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163182734P 2021-04-30 2021-04-30
US63/182,734 2021-04-30
PCT/US2022/026676 WO2022232360A1 (en) 2021-04-30 2022-04-28 Small molecule modulators of glucocerebrosidase activity and uses thereof

Publications (2)

Publication Number Publication Date
JP2024517789A JP2024517789A (ja) 2024-04-23
JP2024517789A5 true JP2024517789A5 (cg-RX-API-DMAC7.html) 2025-05-08

Family

ID=83848814

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023567067A Pending JP2024517789A (ja) 2021-04-30 2022-04-28 グルコセレブロシダーゼ活性の小分子モジュレータ及びその使用

Country Status (10)

Country Link
US (1) US20240246952A1 (cg-RX-API-DMAC7.html)
EP (1) EP4329880A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024517789A (cg-RX-API-DMAC7.html)
KR (1) KR20240016286A (cg-RX-API-DMAC7.html)
CN (1) CN117751114A (cg-RX-API-DMAC7.html)
AU (1) AU2022267285A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023022567A2 (cg-RX-API-DMAC7.html)
CA (1) CA3218510A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023012853A (cg-RX-API-DMAC7.html)
WO (1) WO2022232360A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117820204B (zh) * 2023-12-29 2026-07-24 山东百诺医药股份有限公司 R-3-苄基-3-哌啶甲酰三甲肼的制备方法
WO2025237303A1 (zh) * 2024-05-14 2025-11-20 先声药业有限公司 β-葡萄糖脑苷脂酶变构调节剂、其药物组合物及用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0325956D0 (en) * 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
CA2507348C (en) * 2004-05-13 2013-07-16 The Hospital For Sick Children Real time methylumbelliferone-based assay
EP2350067A2 (en) * 2008-10-16 2011-08-03 Schering Corporation Pyrrolidine, piperidine and piperazine derivatives and methods of use thereof
US8354403B2 (en) * 2009-08-27 2013-01-15 Merck Sharp & Dohme Corp. Pyrrolidine derived beta 3 adrenergic receptor agonists
RU2015147509A (ru) * 2009-10-19 2019-01-14 Амикус Терапьютикс, Инк. Новые композиции для предупреждения и/или лечения дегенеративных расстройств центральной нервной системы
JP2016520532A (ja) * 2013-03-15 2016-07-14 ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ ベンゾイミダゾール誘導体およびその使用
JP2017502961A (ja) * 2013-12-23 2017-01-26 アレクトス セラピューティックス インコーポレイテッド グルコセレブロシダーゼモジュレーターおよびその使用
CN108290855A (zh) * 2015-07-01 2018-07-17 西北大学 被取代的喹唑啉化合物及其调节葡糖脑苷脂酶活性的用途
EP3661919A4 (en) * 2017-08-02 2021-03-31 Northwestern University SUBSTITUTED FUSION PYRIMIDINE COMPOUNDS AND THEIR USES
EP4039685A1 (en) * 2021-02-08 2022-08-10 Irbm S.P.A. Azabicyclic shp2 inhibitors

Similar Documents

Publication Publication Date Title
JP2021534124A5 (cg-RX-API-DMAC7.html)
JP2020183410A5 (cg-RX-API-DMAC7.html)
JP2011509309A5 (cg-RX-API-DMAC7.html)
JP2007508361A5 (cg-RX-API-DMAC7.html)
JP2006504658A5 (cg-RX-API-DMAC7.html)
JP2019505541A5 (cg-RX-API-DMAC7.html)
JP2005508349A5 (cg-RX-API-DMAC7.html)
JP2014516360A5 (cg-RX-API-DMAC7.html)
JP2018518537A5 (cg-RX-API-DMAC7.html)
JP2020507589A5 (cg-RX-API-DMAC7.html)
JP2014506907A5 (cg-RX-API-DMAC7.html)
JP2008195730A5 (cg-RX-API-DMAC7.html)
JP2008513498A5 (cg-RX-API-DMAC7.html)
JP2014503574A5 (cg-RX-API-DMAC7.html)
JP2014507455A5 (cg-RX-API-DMAC7.html)
JP2006523216A5 (cg-RX-API-DMAC7.html)
CA2679198A1 (en) Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
JP2009507909A5 (cg-RX-API-DMAC7.html)
JP2020517707A5 (cg-RX-API-DMAC7.html)
JP2007519649A5 (cg-RX-API-DMAC7.html)
WO2018022992A1 (en) Chemokine receptor modulators and uses thereof
JP2011517697A5 (cg-RX-API-DMAC7.html)
RU2007146669A (ru) Пролекарства антагонистов a2b рецептора аденозина
JP2005539045A5 (cg-RX-API-DMAC7.html)
JP2016508135A5 (cg-RX-API-DMAC7.html)